Bryan Irving
Company: Amunix Pharmaceuticals Inc. – Sanofi
Job title: Chief Scientific Officer
Seminars:
Panel Discussion: Assessing Past Progress Successes with Various Targets 4:30 pm
HER2, PSMA, EPCAM, and CEA antigens present therapeutic opportunity: which of these presents as the most realistic option? Assess the cleanness of these antigen targets Highlight key strategies that can be leveraged to identify the cleanest targetsRead more
day: Day One